Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

doi:10.3748/wjg.v16.i46.5881

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 46

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4060)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

493

HTML

3244

Figures (1-4)

179

Tables (1-2)

144

Sum=4060

Dec 14, 2010 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 14, 2010; 16(46): 5881-5888
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5881

Full Size Figure Download Figure

Figure 2 Progression-free survival time of patients with or without KRAS mutation (A) and phosphatase and tensin protein expression (B). A: P < 0.001; B: P = 0.07. PFS: Progression-free survival.

Citation: Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol 2010; 16(46): 5881-5888
URL: https://www.wjgnet.com/1007-9327/full/v16/i46/5881.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i46.5881